- Home
- HMST vs CLLS Comparison
HMST vs CLLS Comparison
Compare HMST & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- CLLS
- Stock Information
- Founded
- HMST 1921
- CLLS 1999
- Country
- HMST United States
- CLLS France
- Employees
- HMST N/A
- CLLS N/A
- Industry
- HMST Major Banks
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- CLLS Health Care
- Exchange
- HMST Nasdaq
- CLLS Nasdaq
- Market Cap
- HMST 285.7M
- CLLS 240.2M
- IPO Year
- HMST 2012
- CLLS 2007
- Fundamental
- Price
- HMST $14.85
- CLLS $2.24
- Analyst Decision
- HMST Hold
- CLLS Buy
- Analyst Count
- HMST 3
- CLLS 2
- Target Price
- HMST $11.83
- CLLS $8.00
- AVG Volume (30 Days)
- HMST 63.5K
- CLLS 30.7K
- Earning Date
- HMST 10-28-2024
- CLLS 11-04-2024
- Dividend Yield
- HMST 2.69%
- CLLS N/A
- EPS Growth
- HMST N/A
- CLLS N/A
- EPS
- HMST N/A
- CLLS N/A
- Revenue
- HMST $180,519,000.00
- CLLS $19,635,000.00
- Revenue This Year
- HMST N/A
- CLLS $271.02
- Revenue Next Year
- HMST $13.12
- CLLS $33.48
- P/E Ratio
- HMST N/A
- CLLS N/A
- Revenue Growth
- HMST N/A
- CLLS N/A
- 52 Week Low
- HMST $4.20
- CLLS $0.96
- 52 Week High
- HMST $16.10
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- HMST 51.00
- CLLS 49.80
- Support Level
- HMST $14.61
- CLLS $2.30
- Resistance Level
- HMST $16.10
- CLLS $2.41
- Average True Range (ATR)
- HMST 0.58
- CLLS 0.09
- MACD
- HMST -0.13
- CLLS -0.01
- Stochastic Oscillator
- HMST 16.11
- CLLS 50.67
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.